AAV2-hCHM not checked

Spark Therapeutics, Inc.

FollowEvery change as it happens, and a Monday email
Stage
No active trials
 
Next date
None yet
 
Trials
0 active
1 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
Tested for
Choroideremia, CHM (Choroideremia) Gene Mutations
Main trialPhase 1/2
“This clinical study evaluates the safety and tolerability of AAV2-hCHM in participants with Choroideremia gene mutations.”In the company’s words, NCT02341807 on ClinicalTrials.gov

Other drugs for Choroideremia

All 1 drugs for Choroideremia

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1/2Completed 12 Oct 2022 Safety and Dose-escalation Study of AAV2-hCHM in Participants With CHM (Choroideremia) Gene Mutations
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow AAV2-hCHM

Following is part of Solo: you see every change to AAV2-hCHM the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in